We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

FRO:NYSEFrontline Plc Analysis

Data as of 2026-04-04 - not real-time

$36.60

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Frontline plc is trading well above its 20‑day moving average while still above the 50‑day average and comfortably above the 200‑day trend line, indicating a strong bullish bias. The RSI sits in the upper‑mid 60s, supporting continued upside momentum, and the MACD histogram is positive with the line crossing above its signal, reinforcing a bullish technical outlook. Price action is anchored by a solid support near $29.8 and faces resistance just under $37, with the current market price positioned near the top of this range, suggesting limited short‑term upside but strong defensive footing. Volatility remains elevated at roughly 58% over the past month, yet the stock’s beta is below one, tempering systematic market risk. Fundamentally, the company posted nearly 47% revenue growth, exceptional operating margins near 45%, and a free cash flow conversion that comfortably covers its 55% dividend payout, making the 4.8% yield appear sustainable. A discounted cash flow model values the shares around $78, implying roughly a 13% upside from today’s price and supporting an undervalued classification despite the high dividend yield.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 7/10

Key Factors

  • Price near resistance with bullish technical indicators
  • High dividend yield offering immediate income
  • Elevated short‑term volatility

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong forward visibility on VLCC and Suezmax charter rates
  • Undervalued DCF fair value versus current price
  • Sustained high operating margins and cash flow generation

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Robust revenue growth and durable business model in oil transport
  • Consistent dividend with manageable payout ratio
  • Long‑term upside potential reflected in fair‑value gap

Key Metrics & Analysis

Financial Health

Revenue Growth46.70%
Profit Margin19.29%
P/E Ratio21.5
ROE15.63%
ROA6.19%
Debt/Equity122.18
P/B Ratio3.2
Op. Cash Flow$682.5M
Free Cash Flow$544.3M
Industry P/E22.8

Technical Analysis

TrendBullish
RSI62.3
Support$29.82
Resistance$36.98
MA 20$33.50
MA 50$32.33
MA 200$24.45
MACDBullish
VolumeDecreasing
Fear & Greed Index78.8

Valuation

Fair Value$77.94
Target Price$41.25
Upside/Downside12.70%
GradeUndervalued
TypeBlend
Dividend Yield4.81%

Risk Assessment

Beta0.74
Volatility57.75%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.